Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Approved to Start China Trial of PD-L1 in HBV Patients

publication date: Jan 23, 2020

Ascletis Pharma was approved to start China trials of its in-licensed PD-L1 in patients with chronic hepatitis B. One year ago, Ascletis acquired China rights to ASC22 from Suzhou Alphamab for hepatitis B and other viral conditions. Ascletis expects ASC22, a first-in-class, subcutaneously administered PD-L1 antibody, will be effective against HBV, which renders the immune system ineffective through T cell exhaustion. Ascletis has two other potential HBV treatments in pre-clinical development plus a marketed drug, Pegasys®. Ascletis plans to test ASC22 as a monotherapy and in combination with other drugs. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.